Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02751723
Other study ID # APM Project
Secondary ID DRKS00007536
Status Active, not recruiting
Phase
First received
Last updated
Start date September 2014
Est. completion date October 2019

Study information

Verified date March 2019
Source University of Leipzig
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this non-investigational study is to determine the symptoms and disease burden at the time point of diagnosis and in the further course of an incurable cancer disease. The needs and preferences of patients suffering from cancer (ovarian carcinoma, breast cancer, malignant melanoma, lung cancer, stomach cancer, oesophageal cancer, pancreatic cancer, cancer of the hepatobiliary system, colorectal cancer, head and neck cancer) are examined by various validated questionnaires. The data obtained by these questionnaires are collected together with information obtained by the treating physicians at four time points during the study: t0 - patient´s enrollment, at the moment of diagnosis and before the start of tumor therapy, respectively; T1 - 3 months after patient´s enrollment; T2 - 6 months after patient´s enrollment; T3 - 12 months after patient´s enrollment. This highly innovative project offers the chance to identify medical services deficits and risk circumstances for the burden of treatments in an oncology-palliative setting and to optimize the quality of patient care.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 500
Est. completion date October 2019
Est. primary completion date October 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Incurable cancer disease: ovarian carcinoma, breast cancer, malignant melanoma, lung cancer, stomach cancer, oesophageal cancer, pancreatic cancer, cancer of the hepatobiliary system, colorectal cancer, head and neck cancer

- signed and dated Inform Consent Form

- Age = 18 years

Exclusion Criteria:

- Patient is not able to understand and to answer questions

- Patient is in a critical health situation and is directly threatened due to cancer disease or the resulting complications

Study Design


Related Conditions & MeSH terms


Intervention

Other:
validated questionnaires


Locations

Country Name City State
Germany Municipal Hospital Braunschweig Braunschweig
Germany Internal medicine practice Burgwedel
Germany Municipal Hospital Essen-Mitte Essen
Germany University of Essen Essen
Germany University of Göttingen Göttingen
Germany University of Hamburg-Eppendorf Hamburg
Germany Medical University Hanover Hanover
Germany Clinic for Thoraric Diseases (Thoraxklinik) Heidelberg
Germany Municipal Hospital Karlsruhe Karlsruhe
Germany UCCL, University of Leipzig Leipzig Saxony
Germany University of Leipzig, ENT Leipzig
Germany Hospital Leverkusen Leverkusen
Germany Municipal Hospital Magdeburg Magdeburg
Germany University of Mainz Mainz
Germany Maria Hilf Clinic Mönchengladbach
Germany Radiotherapy practice Recklinghausen
Germany University of Regensburg Regensburg
Germany Hospital Südstadt Rostock Rostock
Germany Immanuel Hospital Rüdersdorf Rüdersdorf
Germany Hospital Traunstein Traunstein
Germany Comprehensive Cancer Centre Main-Franken Würzburg

Sponsors (1)

Lead Sponsor Collaborator
Florian Lordick, MD

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Patient´s answers regarding symptom burden at 12 months 12 months after enrollment
Secondary Change from Baseline physician´s report at 12 months 12 months after enrollment
Secondary Change from Baseline Patient´s answers regarding symptom burden at 6 months 6 months after enrollment
Secondary Change from Baseline physician´s report at 6 months 6 months after enrollment
Secondary Change from Baseline Patient´s answers regarding symptom burden at 3 months 3 months after enrollment
Secondary Change from Baseline physician´s report at 3 months 3 months after enrollment